Freddie CEO ignored red flags. Freddie Mac (FRE) CEO Richard Syron chose to ignore internal warnings that, if heeded, could have shielded the GSE fr...
Carl Icahn and friends at ImClone Systems Incorporated (NASDAQ: IMCL) have now formally responded to Bristol-Myers Squibb Company (NYSE: BMY) regardin...
With M&A activity finally going strong within the pharma/biotech markets, we were interested in speaking to Zacks senior pharma & biotech analyst Jaso...
Activist investor Carl Icahn had a nice day yesterday. Here's why:Bristol-Myers (BMY) sent Mr. Icahn a letter presenting a $60 per share offer for ImC...
Thermotoga maritima (green/yellow rods) growing in co-culture with Methanococcus jannaschii (red spheres). T. maritima ferments sugars to hydrogen and...
While most sectors have been faltering for the past month or two, biotechnology has been an exceptional performer, with the top biotech ETF, (IBB), no...
While most sectors have been faltering for the past month or two, biotechnology has been an exceptional performer, with the top biotech ETF, (IBB), no...
Earnings out of Amgen Inc. (NASDAQ: AMGN) appear to be strong enough to defy any notions that the big osteoporosis news would render this particular e...
Jeff Matthews Is Not Making This Up The World of Wall Street in all its glory, and anything else that strikes our fancy. Informed observations about comp...
Stock Market Beat Our beat is the stock market. Our job is to beat it....
TechCrunch TechCrunch profiles the companies, products and events that are defining and transforming the new web. TechCrunch is ...
Trader Mike Stock market commentary & trading ideas. Stock market weblog (blog), swing trading, day trading, stock picks, techni...
Subscribe On Your Mobile
Subscribe
.gif)
Environmental Economics
Paul Kedrosky's Infectious Greed
Jeff Matthews Is Not Making This Up
TechCrunch
Trader Mike
